Summary of significant treatment × time effect. حسب Wensheng Xiao (16557866)

Summary of significant single-arm time effect. حسب Wensheng Xiao (16557866)

Lymphocytes decreased in mouse pneumonia model. حسب Qi Xu (134661)

Mean case duration before and after intervention (t-statistic = -3.35, p <i>< </i>0.001), indicating a statistically significant difference in means. حسب Mohammad Bakhtiari (11838264)

Study selection criteria. حسب Filip Stanicic (17808254)

الموضوعات:

PICOS criteria for the SLR. حسب Filip Stanicic (17808254)

الموضوعات:

PRISMA flow chart. حسب Filip Stanicic (17808254)

الموضوعات:

AdMSC-EVs enhanced colony formation and migration of LECs and decreased proliferation. حسب Xiaoqin Li (1399105)

Voxel-based whole-brain analysis shows regional and dose-dependent effects of netoglitazone in decreasing plaque mean size. حسب Francesca Catto (21253435)

The linearly decreasing convergence factor a. حسب Junhao Wei (6816803)

Average mean decrease Gini across 100 partitions for the top 10 most important variables for binary mixed model and random forest. حسب Helal El-Zaatari (20442243)

miRNA 221 improved left ventricular contractile function in MIRI mice. حسب Hongyu Li (1332669)

The mean and standard deviation of parameters. حسب Sadaf Sepasgozar Sarkhosh (20436143)

الموضوعات:

Significant Decrease in Vessel Count of Trade Vessels in (a) Bosporus Strait and (b) Bab el-Mandeb Strait. حسب Cherryl Chico (20978829)

Average days (mean) to heal a wound in 2022 and 2023. حسب Heba Tallah Mohammed (2822432)

الموضوعات:

Mean Values and Standard Deviations (Mean [±SD]) of Clinical Parameters: periodontal probing depth (PPD), clinical attachment level (CAL), bleeding on probing (BOP), and plaque ind... حسب Iva Milinkovic (22331710)

الموضوعات:

Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf حسب Mi-Ae Lyu (20413646)

"…Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition of ruxolitinib to UCB-Tregs may improve SLE outcomes.…"

Starvation improves locomotory capacity and decreases the number of α-synuclein-YFP aggregates of transgenic <i>C. elegans</i> through LMP-1 dependent mechanism. حسب María Gallardo-Campos (22170919)